Statements (772)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:planet
gptkb:pharmaceuticals gptkb:road gptkb:API gptkb:Demon gptkb:mythical_creatures gptkb:Future gptkb:vaccine |
| gptkbp:accessories |
gptkb:CORBA
|
| gptkbp:acquisition |
gptkb:Ariad_Pharmaceuticals
gptkb:Astra_Zeneca_AB gptkb:Astra_Zeneca_Canada_Inc. gptkb:Astra_Zeneca_PLC gptkb:Med_Immune gptkb:Astra_AB gptkb:Alexion_Pharmaceuticals gptkb:Astra_Pharmaceuticals gptkb:Zeneca_Group gptkb:Astra_Tech Zonagen Acquired Med Immune in 2007 |
| gptkbp:addresses |
cholesterol management
|
| gptkbp:advocacy |
supports patient advocacy groups
|
| gptkbp:aims_to |
improve heart health
|
| gptkbp:aims_to_improve |
gptkb:healthcare_access
gptkb:healthcare_professionals quality of life for patients healthy lifestyles patient adherence healthcare disparities early diagnosis treatment outcomes cardiovascular health initiatives access to treatments cardiovascular mortality hospitalizations due to heart disease |
| gptkbp:annual_report |
publishes annual reports
|
| gptkbp:application |
gptkb:crypt
gptkb:Telecommunications gptkb:medical_devices industrial automation automotive systems signal processing consumer appliances |
| gptkbp:are_known_for |
gptkb:item
magical powers their own realms great armies their own hierarchies their own rituals their own legends their own myths their own philosophies their strength and magical powers |
| gptkbp:are_known_to_challenge |
the authority of Indra
|
| gptkbp:are_part_of |
gptkb:cosmology
cosmic struggle between good and evil |
| gptkbp:assets |
cardiovascular assets
|
| gptkbp:associated_with |
gptkb:the_underworld
gptkb:mythology the concept of duality chaos the concept of sacrifice the quest for immortality the cycle of rebirth the pursuit of power the concept of illusion the battle of good and evil |
| gptkbp:atmosphere |
yes
|
| gptkbp:average_temperature |
2 to 8 degrees Celsius
15 ° C |
| gptkbp:awards |
Top Employer 2021
Best Workplaces 2020 Sustainability Leader 2021 |
| gptkbp:belongs_to |
asyncio
|
| gptkbp:benefits |
gptkb:FPGA
small size high performance low power consumption Standard Chips |
| gptkbp:biopharmaceuticals |
focus on biopharmaceuticals
|
| gptkbp:can_be |
gptkb:mythical_creatures
symbolic representations benevolent or malevolent cautionary tales. |
| gptkbp:can_be_used_in |
gptkb:Consumer_Electronics
gptkb:networking gptkb:medical_devices Automotive Applications |
| gptkbp:capital |
over $100 billion
|
| gptkbp:ceo |
gptkb:Pascal_Soriot
|
| gptkbp:challenges |
design complexity
market demand fluctuations risk of obsolescence high non-recurring engineering costs long lead times |
| gptkbp:characteristic |
gptkb:Exception
loop result cancelled done |
| gptkbp:characterized_by |
High Efficiency
High Performance Low Power Consumption desire and ambition |
| gptkbp:clinical_research_sites |
worldwide
multiple sites worldwide |
| gptkbp:clinical_trial |
gptkb:vaccine
over 30,000 ongoing Phase II Phase 3 Phase III innovative biopharmaceuticals global presence Phase I collaborative Phase III trials cancer treatments new drug development Phase I trials Phase II trials over 100 ongoing conducts clinical trials various drugs vaccine trials cardiovascular drugs over 200 ongoing patient-centric I, II, III, IV extensive clinical data invests in clinical research Phase I to IV phases I, II, III conducted with University of Alberta conducted with University of Calgary focus on oncology and respiratory diseases global clinical research in collaboration with University of Calgary shared with research partners conducts various clinical trial phases involved in drug development publishes clinical data |
| gptkbp:collaborates_with |
research institutions
|
| gptkbp:collaboration |
gptkb:University_of_Ottawa_Heart_Institute
gptkb:GSK gptkb:University_of_California_Davis gptkb:University_of_California_Irvine gptkb:University_of_California_Los_Angeles gptkb:University_of_California_San_Diego gptkb:University_of_California_San_Francisco gptkb:University_of_California_Santa_Barbara gptkb:University_of_California_Santa_Cruz gptkb:Oxford_University gptkb:Pfizer gptkb:Merck_&_Co. COVID-19 vaccine development |
| gptkbp:collaborations |
gptkb:University_of_Calgary
gptkb:University_of_Manchester gptkb:University_of_Alberta government agencies academic institutions collaborative partnerships biotech companies with universities with healthcare organizations engages in collaborative research |
| gptkbp:collaborative_projects |
with various universities
|
| gptkbp:color |
gptkb:blue
|
| gptkbp:community_engagement |
community engagement initiatives
|
| gptkbp:community_health |
gptkb:commitment
various programs engages in global health initiatives |
| gptkbp:conducts |
clinical trials
|
| gptkbp:conducts_research_on |
gptkb:Mene_Pangalos
multiple directors multiple global locations multiple research heads |
| gptkbp:contraindication |
allergy to components
|
| gptkbp:country |
gptkb:United_Kingdom
2 |
| gptkbp:covid-19_impact |
vaccine development
collaboration with University of Oxford |
| gptkbp:dedicated_to |
patient safety
|
| gptkbp:defeated |
the Devas
|
| gptkbp:depicted_in |
art and literature
fearsome beings fearsome creatures |
| gptkbp:designed_for |
Specific Applications
specific applications |
| gptkbp:developed_by |
gptkb:Astra_Zeneca_PLC
Semiconductor Companies semiconductor manufacturers |
| gptkbp:development |
diverse and inclusive
longer than FPGAs |
| gptkbp:develops |
antiplatelet agents
beta-blockers medications for cardiovascular conditions |
| gptkbp:diameter |
12,742 km
|
| gptkbp:discovered_by |
gptkb:unknown
|
| gptkbp:distance_from_earth |
1 AU
|
| gptkbp:divisions |
pharmaceuticals and biologics
|
| gptkbp:dosage_form |
2
yes |
| gptkbp:drug_approvals |
receives drug approvals from regulatory bodies
|
| gptkbp:drug_pipeline |
extensive drug pipeline
|
| gptkbp:emergency_services |
multiple countries
|
| gptkbp:employees |
over 70,000
70,600 (2020) approximately 70,600 |
| gptkbp:events |
gptkb:unknown
|
| gptkbp:example |
consumer electronics
networking devices Bitcoin mining hardware |
| gptkbp:financial_performance |
strong growth
|
| gptkbp:financial_support |
offers patient support programs
|
| gptkbp:first_dose_administration |
gptkb:2020
|
| gptkbp:focus |
Pharmaceuticals
biopharmaceuticals |
| gptkbp:focus_area |
oncology
infectious diseases autoimmunity cardiovascular respiratory |
| gptkbp:focuses_on |
cardiovascular diseases
|
| gptkbp:formed |
merger of Astra AB and Zeneca Group
|
| gptkbp:founded |
gptkb:1999
|
| gptkbp:founder |
merger of Astra AB and Zeneca Group
|
| gptkbp:funding |
from government and private sectors
provides research funding significant investment in R& D |
| gptkbp:future_prospects |
integration with other technologies
advancements in fabrication technology increased use in AI more specialized designs potential for quantum computing applications |
| gptkbp:global_presence |
over 100 countries
operates in over 100 countries cardiovascular market |
| gptkbp:has_collaborations_with |
biotechnology firms
pharmaceutical partners |
| gptkbp:has_conflict_with |
gptkb:gods
the Devas |
| gptkbp:has_connection_to |
ancient rituals
|
| gptkbp:has_developed |
new treatment protocols
new diagnostic tools cholesterol-lowering medications new anticoagulants |
| gptkbp:has_diversity_initiatives |
various programs
inclusive workplace promoting workplace diversity focus on diversity initiatives |
| gptkbp:has_influence_on |
modern interpretations
|
| gptkbp:has_lore |
their origin
|
| gptkbp:has_method |
gptkb:Exception
result cancelled set_exception cancel done add_done_callback set_result |
| gptkbp:has_part |
cardiovascular portfolio
|
| gptkbp:has_partnerships_with |
academic institutions
|
| gptkbp:has_property |
great strength
immense knowledge |
| gptkbp:has_relationship_with |
gptkb:Brahman
|
| gptkbp:has_research_areas |
heart disease
|
| gptkbp:has_research_center |
gptkb:Cambridge
gptkb:Gaithersburg gptkb:Sodertalje gptkb:Moscow gptkb:Shanghai |
| gptkbp:has_research_focus |
cardiovascular epidemiology
cardiovascular pharmacology cardiovascular biomarkers thromboembolic disorders |
| gptkbp:has_role |
moral lessons
the balance of nature the creation of the universe cosmic battles the moral fabric of stories the teachings of dharma the evolution of mythology |
| gptkbp:has_type |
Sura and Asura
|
| gptkbp:has_variations |
different cultures
|
| gptkbp:head_of_global_biopharmaceuticals |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_cardiovascular |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_communications |
gptkb:Megan_Mc_Carthy
|
| gptkbp:head_of_global_finance |
gptkb:Marc_Dunoyer
|
| gptkbp:head_of_global_human_resources |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_immunology |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_infectious_diseases |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_information_technology |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_legal_affairs |
gptkb:Mark_Mc_Clellan
|
| gptkbp:head_of_global_marketing |
gptkb:Rupert_Vessey
|
| gptkbp:head_of_global_neuroscience |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_oncology |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_pharmaceuticals |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_quality |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_rare_diseases |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_regulatory_affairs |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_respiratory |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_strategy |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_supply |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_sustainability |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_therapeutic_area |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_therapeutic_area_cardiovascular |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_therapeutic_area_immunology |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_therapeutic_area_infectious_diseases |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_therapeutic_area_neuroscience |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_therapeutic_area_oncology |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_therapeutic_area_rare_diseases |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_therapeutic_area_respiratory |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_therapeutic_area_therapeutic_area |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_therapeutic_area_therapeutics |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_therapeutics |
gptkb:Michele_Garufi
|
| gptkbp:head_of_global_vaccines |
gptkb:Michele_Garufi
|
| gptkbp:head_of_state |
gptkb:David_Smith
various executives multiple operational heads |
| gptkbp:headcount |
over 70,000
|
| gptkbp:headquarters |
gptkb:Cambridge,_England
gptkb:Cambridge,_UK |
| gptkbp:healthcare |
gptkb:Lynparza
gptkb:Astra_Zeneca's_monoclonal_antibodies gptkb:Breztri_Aerosphere gptkb:Astra_Zeneca's_vaccines gptkb:Brilinta gptkb:Calquence gptkb:Dapagliflozin gptkb:Fasenra gptkb:Faslodex gptkb:Imfinzi gptkb:Movantik gptkb:Mylotarg gptkb:Saphnelo gptkb:Selumetinib gptkb:Tagrisso gptkb:Trixeo_Aerosphere gptkb:Astra_Zeneca_COVID-19_vaccine gptkb:Tafinlar gptkb:Symbicort gptkb:Vaxzevria gptkb:Zoladex gptkb:Nexium gptkb:Farxiga gptkb:Seroquel innovative improves healthcare access developed for patients providing innovative treatments. Epaned Brilique |
| https://www.w3.org/2000/01/rdf-schema#label |
Astra Zeneca
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:influences |
Indian culture
Buddhist mythology |
| gptkbp:innovation |
gptkb:gene_therapy
biologics small molecules focus on innovation focus on science focus on biopharmaceuticals |
| gptkbp:instruction_set |
diverse
innovative therapies high unmet medical need |
| gptkbp:invention |
numerous
numerous patents holds numerous patents thousands of patents worldwide in pharmaceuticals |
| gptkbp:investment |
gptkb:public_company
research and development biomedical research cardiovascular research in biotechnology invests in R& D |
| gptkbp:involved_in |
gptkb:the_churning_of_the_ocean
|
| gptkbp:is |
Used in Security Systems
Used in Aerospace Applications Used in Robotics Used in AI Applications Used in Cloud Computing Used in Edge Computing Used in Machine Learning Used in Augmented Reality Devices Used in Image Processing Used in Virtual Reality Devices Used in Wearable Technology Used in Financial Services Used in Data Centers Used in Telecommunications Equipment Used in Video Games Non-Programmable Task-Specific Used in 5 G Technology Used in Agricultural Technology Used in Audio Equipment Used in Bitcoin Mining Used in Blockchain Technology Used in Broadcast Technology Used in Cybersecurity Solutions Used in Data Analytics Used in Digital Cameras Used in Energy Management Systems Used in Environmental Monitoring Used in High-Frequency Trading Used in Home Appliances Used in Industrial Automation Used in Io T Devices Used in Satellite Communications Used in Smart Cities Used in Smart Devices Used in Smart Grids Used in Telecommunications Infrastructure Used in Video Encoding |
| gptkbp:is_active_in |
global markets
healthcare research clinical research |
| gptkbp:is_associated_with |
the material world
chaos and disorder the concept of Maya |
| gptkbp:is_believed_to |
great wealth
|
| gptkbp:is_compared_to |
gptkb:FPGA
Devas general-purpose processors General-Purpose Processors |
| gptkbp:is_considered |
powerful beings
|
| gptkbp:is_effective_against |
approximately 76%
|
| gptkbp:is_engaged_in |
community outreach programs
public health campaigns patient education initiatives patient advocacy. |
| gptkbp:is_explored_in |
gain power over the heavens
|
| gptkbp:is_featured_in |
various films and literature
various Hindu texts |
| gptkbp:is_focused_on |
preventive measures
innovative solutions long-term outcomes chronic heart conditions |
| gptkbp:is_found_in |
Vedic texts
|
| gptkbp:is_involved_in |
gptkb:the_churning_of_the_ocean
preventive cardiology global health challenges healthcare innovation patient support programs cardiovascular risk assessment healthcare policy advocacy medical education initiatives the cycle of rebirth clinical guidelines development clinical practice improvement multinational studies healthcare collaborations |
| gptkbp:is_known_for |
collaborative research efforts
innovative therapies patient engagement strategies clinical excellence therapeutic advancements |
| gptkbp:is_linked_to |
the concept of Maya
|
| gptkbp:is_mentioned_in |
gptkb:Buddhism
gptkb:Puranas various Hindu texts |
| gptkbp:is_often_associated_with |
gptkb:the_underworld
the night the concept of Maya |
| gptkbp:is_often_compared_to |
the concept of Dharma
|
| gptkbp:is_often_depicted_as |
gptkb:folklore
gptkb:poetry gptkb:traditional_dance gptkb:mythology gptkb:cosmology gptkb:weapons cultural festivals epic tales temple sculptures modern media tricksters dance and performance multiple heads guardians of treasures mythical animals powerful and ambitious beautiful beings having multiple heads fearsome beings benevolent beings enemies of the gods guardians of the underworld cunning and deceitful demonic figures traditional stories. having dark skin having fierce expressions |
| gptkbp:is_often_described_as |
fallen angels
their desire for power |
| gptkbp:is_often_involved_in |
cosmic battles
mythological battles the creation of obstacles for the gods |
| gptkbp:is_often_seen_in |
gptkb:antagonist
forces of nature guardians of the underworld fallen angels representatives of chaos representatives of ignorance symbols of human flaws the embodiment of ego the source of temptation. |
| gptkbp:is_opposed_by |
gptkb:developers
Devas |
| gptkbp:is_recognized_for |
patient-centered care
scientific contributions |
| gptkbp:is_vulnerable_to |
gptkb:WHO_Emergency_Use_Listing
gptkb:significant gptkb:Astra_Zeneca_COVID-19_vaccine gptkb:Vaxzevria gptkb:Covishield December 2020 global ongoing international collaborations safety monitoring mixed responses public and private sectors logistical issues over 1 billion doses collaborative effort complex supply chain viral vector technology generally mild stable at refrigerator temperatures standard refrigeration against hospitalization against symptomatic infection important for uptake conditional approval against death in vaccine technology 76% (initial data) COVID-19 vaccine with University of Calgary collaborated with University of Alberta developed a vaccine distributes vaccines globally reduction in hospitalization reduction in transmission important for global health efforts reduction in severe disease |
| gptkbp:is_worshipped_by |
certain sects
|
| gptkbp:key_people |
gptkb:Pascal_Soriot
|
| gptkbp:known_for |
power and strength
|
| gptkbp:manufacturer |
multiple countries
Photolithography |
| gptkbp:manufacturing_process |
photolithography
|
| gptkbp:market |
global
growing global market |
| gptkbp:market_cap |
approximately $140 billion
$140 billion (2021) significant market capitalization |
| gptkbp:market_position |
global
strong in Europe and North America |
| gptkbp:notable_products |
gptkb:Astra_Zeneca_COVID-19_vaccine
|
| gptkbp:number_of_employees |
over 70,000
|
| gptkbp:offers |
treatments for hypertension
|
| gptkbp:orbital_period |
365 days
|
| gptkbp:originated_in |
gptkb:mythology
|
| gptkbp:parent_company |
gptkb:Astra_Zeneca_PLC
|
| gptkbp:partnership |
gptkb:Eli_Lilly
gptkb:University_of_Ottawa gptkb:GSK gptkb:University_of_Toronto_Mississauga gptkb:Takeda_Pharmaceutical_Company gptkb:Sanofi gptkb:Boehringer_Ingelheim gptkb:Bristol-Myers_Squibb gptkb:Oxford_University gptkb:University_of_Calgary gptkb:University_of_California gptkb:University_of_Cambridge gptkb:University_of_Edinburgh gptkb:University_of_Manchester gptkb:University_of_Oxford gptkb:University_of_Toronto gptkb:Janssen_Pharmaceuticals gptkb:University_of_Melbourne gptkb:University_of_Queensland gptkb:University_of_Sydney gptkb:University_of_Alberta gptkb:Merck_&_Co. gptkb:Amgen gptkb:Daiichi_Sankyo healthcare providers Astra Zeneca and the University of British Columbia Astra Zeneca and the University of Alberta Astra Zeneca and the University of Calgary Astra Zeneca and the University of California Astra Zeneca and the University of Cambridge Astra Zeneca and the University of Edinburgh Astra Zeneca and the University of Manchester Astra Zeneca and the University of Melbourne Astra Zeneca and the University of Ottawa Astra Zeneca and the University of Oxford Astra Zeneca and the University of Queensland Astra Zeneca and the University of Sydney Astra Zeneca and the University of Toronto Astra Zeneca and the University of Toronto Mississauga partnership with Oxford University Partnership with various research institutions Oxford University for COVID-19 vaccine |
| gptkbp:partnerships |
gptkb:GAVI_Alliance
gptkb:CEPI gptkb:University_of_Oxford gptkb:WHO COVID-19 vaccine development hospitals academic institutions research institutions various universities various academic institutions multiple universities with healthcare institutions collaborations with universities with academic institutions with global health organizations collaborations with biotech companies partners with healthcare organizations |
| gptkbp:philanthropy |
gptkb:Astra_Zeneca_Foundation
|
| gptkbp:pipeline_drugs |
over 180
|
| gptkbp:price |
higher initial cost
|
| gptkbp:products |
gptkb:vaccine
medications vaccines drugs oncology drugs cardiovascular drugs respiratory drugs |
| gptkbp:programming_language |
not programmable after manufacturing
|
| gptkbp:provides |
solutions for heart failure
|
| gptkbp:provides_guidance_on |
developed
contributes to clinical guidelines developed for healthcare providers developed for various treatments |
| gptkbp:publications |
publishes scientific publications
|
| gptkbp:regulatory_compliance |
gptkb:European_Medicines_Agency
gptkb:U._S._Food_and_Drug_Administration must comply with safety standards ensures regulatory compliance subject to industry standards environmental regulations apply export controls may apply intellectual property laws affect design |
| gptkbp:related_to |
gptkb:Apsaras
|
| gptkbp:represents |
natural forces
chaos and disorder the darker aspects of humanity the struggle for existence |
| gptkbp:requires |
High Initial Investment
Custom Design |
| gptkbp:research |
oncology
immunology cardiovascular respiratory |
| gptkbp:research_and_development |
oncology
biopharmaceuticals over $6 billion annually $6.1 billion (2020) |
| gptkbp:research_areas |
gptkb:diabetes
neurology oncology rare diseases neuroscience infectious diseases immunology multiple therapeutic areas cardiovascular respiratory cardiovascular, renal, and metabolism |
| gptkbp:research_focus |
oncology
biologics immunology cardiovascular respiratory |
| gptkbp:revenue |
over $30 billion
approximately $30 billion approximately $37 billion over $26 billion $37 billion (2020) $26.6 billion (2020) over $26 billion (2020) |
| gptkbp:side_effect |
fatigue
headache muscle pain nausea fever |
| gptkbp:social_responsibility |
gptkb:healthcare_access
community engagement community support education initiatives various initiatives engages in corporate social responsibility commitment to health and education |
| gptkbp:stock_exchange |
gptkb:NYSE
gptkb:LSE listed on the London Stock Exchange |
| gptkbp:stock_symbol |
AZN
|
| gptkbp:strategic_goals |
cardiovascular sector
|
| gptkbp:subsidiaries |
gptkb:Astra_Zeneca_UK_Limited
gptkb:Astra_Zeneca_PLC gptkb:Med_Immune gptkb:Alexion_Pharmaceuticals gptkb:Astra_Zeneca_Pharmaceuticals_LP |
| gptkbp:subsidiary |
gptkb:Astra_Zeneca_PLC
gptkb:Alexion_Pharmaceuticals |
| gptkbp:supply_chain |
global network
manages a global supply chain |
| gptkbp:sustainability |
focus on sustainability
|
| gptkbp:sustainability_initiatives |
community engagement
carbon neutrality by 2025 environmental responsibility healthcare innovation various initiatives access to medicines environmental responsibility programs environmental goals |
| gptkbp:symbolizes |
ego and pride
|
| gptkbp:targets |
gptkb:COVID-19
atherosclerosis |
| gptkbp:therapeutic_innovations |
in various fields
|
| gptkbp:therapeutic_pipeline |
diverse
|
| gptkbp:traded_on |
gptkb:LSE
|
| gptkbp:training |
development programs
ongoing professional development programs provides employee training programs |
| gptkbp:treatment |
improved clinical outcomes
|
| gptkbp:trends |
energy efficiency
customization increased integration miniaturization higher performance lower costs |
| gptkbp:type |
gptkb:public_company
viral vector vaccine |
| gptkbp:type_of |
gptkb:Demon
|
| gptkbp:used_in |
gptkb:Telecommunications
Digital Signal Processing Cryptocurrency Mining digital circuits |
| gptkbp:uses_technology |
focus area
|
| gptkbp:vaccine_administration_route |
intramuscular
|
| gptkbp:vaccine_clinical_trial_results |
published in medical journals
|
| gptkbp:vaccine_collaboration |
with WHO
|
| gptkbp:vaccine_communication_strategies |
critical for public trust
|
| gptkbp:vaccine_community_health |
improves community health
|
| gptkbp:vaccine_crisis_response |
part of pandemic response
|
| gptkbp:vaccine_efficacy_against_variants |
reduced efficacy
|
| gptkbp:vaccine_ethical_considerations |
equitable distribution
|
| gptkbp:vaccine_future_research |
focus on variants
|
| gptkbp:vaccine_global_access |
increased access
|
| gptkbp:vaccine_impact_on_herd_immunity |
contributes to herd immunity
|
| gptkbp:vaccine_long_term_studies |
ongoing studies
|
| gptkbp:vaccine_production_capacity |
increased production
|
| gptkbp:vaccine_public_health_policy |
influences policy decisions
|
| gptkbp:vaccine_regulatory_challenges |
navigating approvals
|
| gptkbp:vaccine_technology |
gptkb:virus
|
| gptkbp:website |
www.astrazeneca.com
astrazeneca.com |
| gptkbp:whoemergency_use_listing |
yes
|
| gptkbp:bfsParent |
gptkb:biotechnology
gptkb:W3_C |
| gptkbp:bfsLayer |
3
|